Publication details
Why are not all eligible chronic myeloid leukemia patients willing to attempt tyrosine kinase inhibitor discontinuation? A Czech nationwide analysis related to the TKI stopping trial HALF
| Authors | |
|---|---|
| Year of publication | 2024 |
| Type | Article in Periodical |
| Magazine / Source | Leukemia |
| MU Faculty or unit | |
| Citation | |
| Web | https://www.nature.com/articles/s41375-024-02215-9 |
| Doi | http://dx.doi.org/10.1038/s41375-024-02215-9 |
| Description | Tyrosine kinase inhibitor (TKI) therapy discontinuation with the aim of achieving treatment-free remission (TFR) is becoming more frequent, as an increasing number of chronic myeloid leukemia (CML) patients are achieving stable deep molecular response (DMR; i.e. BCR::ABL1 transcript level ?0.01% on the International Scale); however, many challenges remain unresolved. Among others, a nonnegligible proportion of patients reported fear, anxiety, or depression both during TFR and when they had to reinitiate TKI therapy. Similar negative feelings are frequently mentioned in the context of the decision to not stop TKI treatment; furthermore, a considerable proportion of patients (17–50%) have been reported to be unwilling to attempt TFR. However, little is known about how many truly eligible patients are unwilling to attempt TFR, the reasons for their decision and what factors are associated with their unwillingness to discontinue long-term therapy since the reports mentioned above have substantial limitations. The surveys were often conducted in a limited number of centres, focused on patients who are able to use internet tools, focused on more educated patients who are connected to patient supportive organisations, and usually not specifically focused on patients who fulfilled the criteria for TKI discontinuation. |
| Related projects: |
|